Digestive Diseases and Sciences

, Volume 41, Issue 10, pp 2048–2054 | Cite as

Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer

  • Robert-J. M. Brummer
  • Reinhold W. Stockbrügger
Esophageal, Gastric, And Duodenal Disorders


The study investigated the effect of either nocturnal acid suppression by the H2 antagonist nizatidine 300 mg at night or prolonged acid suppression by the proton-pump inhibitor omeprazole 20 mg in the morning, during four weeks, on intragastric pH profile, occurrence of bacterial growth in gastric fluid and biopsies, and healing rate in 23 patients with an acute duodenal ulcer. The endoscopic healing rate did not differ significantly between the two treatment modalities. The 24-hr acid secretion was significantly more reduced by omeprazole than nizatidine (P<0.002). After treatment by nizatidine and omeprazole, respectively, median 24-hr intragastric pH increased from 1.5 to 1.8 (P<0.01) and from 1.5 to 6.1 (P<0.01), respectively. Nighttime acid inhibition did not differ significantly. The difference in gastric bacterial colonization after either omeprazole or nizatidine did not reach significance. However, median 24-hr pH and the fraction of the day with pH<3 and pH<4 were significantly correlated to bacterial colonization of the gastric fluid (P<0.05).

Key words

nizatidine omeprazole 24-hr intragastric pH monitoring acid inhibition bacterial growth 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burget DW, Chiverton SG, Hunt RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers? Gastroenterology 99:345–351, 1990PubMedGoogle Scholar
  2. 2.
    Bell NJ, Burget D, Howden C, Wilkinson J, Hunt RH: Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 51(suppl 1):59–67, 1992PubMedGoogle Scholar
  3. 3.
    Smith PM, Kerr GD, Cockel R, Ross BA, Bate CM, Brown P, Dronfield MW, Green JRB, Hislop WS, Theodossi A, McFarland RJ, Watts DA, Taylor MD, Richardson PDI, Bradby GVH, Bullimore GVH, Davies M, Dickinson RJ, Edwards MH, et al: A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 107:1312–1318, 1994PubMedGoogle Scholar
  4. 4.
    Hallerbäck B, Unge P, Carling L, Edwin B, Glise H, Havu N, Lyrenäs E, Lundberg K: Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 107:1305–1311, 1994PubMedGoogle Scholar
  5. 5.
    Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH: Acid suppression in duodenal ulcer. A meta-analysis to define optimal dosing with antisecretory drugs. Gut 28:1120–1127, 1987PubMedGoogle Scholar
  6. 6.
    Hunt RH: The protective role of gastric acid. Scand J Gastroenterol 23(suppl 146):34–39, 1988Google Scholar
  7. 7.
    Wilder-Smith CH, Spirig C, Krech T, Merki HS: Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol 4:885–891, 1992Google Scholar
  8. 8.
    Husebye E, Skar V, Hoverstad T, Melby K: Fasting hypochlorhydria with gram positive flora is highly prevalent in healthy old people. Gut 33:1331–1337, 1992PubMedGoogle Scholar
  9. 9.
    Thomas JM, Misciewicz JJ, Cook AR, Hill MJ, Smith PL, Walters CL, Forster JK, Martin LE, Woodings DF: Effects of one year's treatment with ranitidine and of truncal vagotomy on gastric contents. Gut 28:726–738, 1987PubMedGoogle Scholar
  10. 10.
    Enander LK, Nilsson F, Ryden AC, Schwan A: The aerobic and anaerobic microflora of the gastric remnant more than 15 years after Billroth II resection. Scand J Gastroenterol 17:715–720, 1982PubMedGoogle Scholar
  11. 11.
    Snepar R, Proporad GA, Romano JM, Kobasa WD, Kaye D: Effect of cimetidine and antacid on gastric microbial flora. Infect Immun 36:518–524, 1982PubMedGoogle Scholar
  12. 12.
    Du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon J: Aspiration of gastric bacteria in antacid-treated patients: A frequent cause of postoperative colonisation of the airway. Lancet 1:242–245, 1982PubMedGoogle Scholar
  13. 13.
    Milton-Thompson GJ, Lightfoot NF, Ahmet Z, Hunt RH, Barnard J, Barin PMG, Brimblecombe RW, Darkin DW, Moore PJ, Viney N: Intragastric acidity, bacteria, nitrite, andN-nitroso compounds before, during and after cimetidine treatment. Lancet 1:1091–1095, 1982PubMedGoogle Scholar
  14. 14.
    Stockbrügger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL: Intragastric nitrites, nirosamines, and bacterial overgrowth during cimetidine treatment. Gut 23:1048–1054, 1982PubMedGoogle Scholar
  15. 15.
    Sharma BK, Santana IA, Wood EC, Walt RP, Pereira M, Noone P, Smith PLR, Walters CL, Pounder RE: Intragastric bacterial activity and nitrosation before, during and after treatment with omeprazole. BMJ 289:717–719, 1984PubMedGoogle Scholar
  16. 16.
    Verdu E, Viani F, Armstrong D, Fraser R, Siegrist HH, Pignatelli B, Idström J-P Cederberg C, Blum AL, Fried M: Effects of omeprazole on intragastric bacterial counts, nitrates, nitrites, andN-nitroso compounds. Gut 35:445–460, 1994PubMedGoogle Scholar
  17. 17.
    Reed P, Smith P, Haines K, House FR, Walters CL: Effect of cimetidine on gastric juiceN-nitrosamine concentration. Lancet 2:553–556, 1981PubMedGoogle Scholar
  18. 18.
    Hall CN, Darkin D, Brimblecombe R, Cook AJ, Kirkham JS, Northfield TC: Evaluation of the nitrosamine hypothesis of gastric carcinogenesis in precancerous conditions. Gut 27:491–498, 1986PubMedGoogle Scholar
  19. 19.
    Northfield TC, Hall CN: Carcinoma of the gastric stump: Risks and pathogenesis. Gut 31:1217–1219, 1990PubMedGoogle Scholar
  20. 20.
    Wilder-Smith CH, Gennoni A, Triller J, Scheurer U, Merki HS: Is a fluoroscopic verification of the electrode position necessary in ambulatory intragastric pH monitoring? Digestion 52:1–5, 1992PubMedGoogle Scholar
  21. 21.
    Merki H, Witzel L, Walt RP, Cohnen E, Harre K, Heim J, Mappes A, Rohmel J: Day-to-day variations of 24-hour intragastric acidity. Gastroenterology 94:887–891, 1988PubMedGoogle Scholar
  22. 22.
    Pounder RE, Fraser AG: Gastric acid secretion and intragastric acidity: measurement in health and disease. Ballieres Clin Gastroenterol 7:55–80, 1993Google Scholar
  23. 23.
    Wolfhagen FHJ, van Engelshoven I, Brummer RJM, Zeijen RNM, Bonnemayers GPM, Stockbrügger RW: Intragastric pH and serum cortisol levels in shift workers, with special reference to eating and working patterns. Eur J Gastroenterol Hepatol 6:313–320, 1994Google Scholar
  24. 24.
    Feldman M, Richardson CT: Total 24-hour gastric acid secretion in patients with duodenal ulcer. Gastroenterology 90:540–544, 1986PubMedGoogle Scholar
  25. 25.
    Merki HS, Fimmel CJ, Walt RP, Harre K, Rohmel J, Witzel L: Pattern of 24-hour intragastric acidity in active duodenal ulcer disease and in healthy controls. Gut 29:1583–1587, 1988PubMedGoogle Scholar
  26. 26.
    Chiverton SG, Howden CW, Burget DW, Hunt RW: Omeprazole (20 mg) daily given in the morning or evening: A comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 6:103–111, 1992PubMedGoogle Scholar
  27. 27.
    Houben GMP, Hooi J, Hameeteman W, Stockbrügger RW: Twenty-four-hour intragastric acidity: Ranitidine 300 mg BID, omeprazole 20 mg OM, omeprazole 40 mg OM versus placebo. Aliment Pharmacol Ther 1995 (in press)Google Scholar
  28. 28.
    Dammann HG, Gottlieb WR, Walter ThA, Dreyer M, Müller P, Simon B, Keohane P: Nocturnal acid suppression with a new H2-receptor antagonist—nizatidine. Hepato-Gastroenterol 33:217–220, 1986Google Scholar
  29. 29.
    Lanzon-Miller S, Pounder RE, Chronos NAF, Raymond F, Hamilton MR, Dalgleish D: Twenty-four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 2100 h. Gut 29:1364–1369, 1988PubMedGoogle Scholar
  30. 30.
    Stockbrügger RW, Seeberg S, Hellner L, Jaup BH, Dotevall G: Intragastric bacteria and nitrite after short-term treatment with different doses of antimuscarinic drugs. Scand J Gastroenterol 19:14–23, 1984PubMedGoogle Scholar
  31. 31.
    Hamilton I, Wormsley BW, O'Connor HJ, Axon A: Effects of tripotassium dicitrato bismuthate (TDB) tablets or cimetidine in the treatment of duodenal ulcer. Gut 24:1148–1151, 1983PubMedGoogle Scholar
  32. 32.
    Garvey BM, McCambley JA, Tuxen DV: Effects of gastric alkalization on bacterial colonization in critically ill patients. Crit Care Med 17:211–216, 1989PubMedGoogle Scholar
  33. 33.
    Reusser P, Zimmerli W, Scheidegger D, Marbet GA, Buser M, Gyr K: Role of gastric colonization in nosocomial infections and endotoxemia: A prospective study in neurosurgical patients on mechanical ventilation. J Infect Dis 160:414–421, 1989PubMedGoogle Scholar
  34. 34.
    Stockbrügger RW: Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol S111:7–16, 1985Google Scholar
  35. 35.
    Hill M: Gastric carcinogenesis: luminal factors.In Carcinogenesis. P Reed, M Hill (eds). Amsterdam, Elsevier, 1988, pp 187–199Google Scholar
  36. 36.
    Pignatelli B, Malaveille C, Rogatko A, Hautefeuille A, Thuillier P, Munoz N, Moulinier B, Berger F, De Montclos H, Lambert R, Correa P, Ruiz B, Sobala GM, Schorah CJ, Axon ATR, Bartsch H: Mutagens,N-nitroso compounds and their precursors in gastric juice from patients with and without precancerous lesions of the stomach. Eur J Cancer 29A:2031–2039, 1993PubMedGoogle Scholar
  37. 37.
    Tannenbaum SR:N-Nitroso compounds: A perspective on human exposure. Lancet 1:629–631, 1983PubMedGoogle Scholar
  38. 38.
    Stockbrügger RW, Cotton PB, Menon GG, Beilby JO, Bartholomew BA, Hill MJ, Walters CL: Pernicious anaemia, intragastric bacterial overgrowth, and possible consequences. Scand J Gastroenterol 19:355–364, 1984PubMedGoogle Scholar
  39. 39.
    Houben GMP, Stockbrügger RW: Bacteria in the aetiopathogenesis of gastric cancer: a review. Scand J Gastroenterol 30(S212):13–18, 1995Google Scholar
  40. 40.
    Houben G, Hooi J, Hameeteman W, Stobberingh E, Stockbrügger RW: Intragastric bacterial growth, nitrite, and total nitroso compounds after short term treatment of healthy subjects with various doses of acid reducing drugs. Gastroenterology 106:A96, 1994Google Scholar
  41. 41.
    Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gonvers JJ, Gyr K, Fried M: Higher incidence of bacterial overgrowth during treatment with omeprazole as compared to cimetidine:a prospective randomized double-blind study. Gastroenterology 106:A197, 1994Google Scholar
  42. 42.
    Fried M, Siegriest H, Frei R, Fröhlich F, Duroux P, Thorens J, Blum A, Bille J, Gonvers JJ, Gyr K: Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 35:23–26, 1994PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Robert-J. M. Brummer
    • 1
  • Reinhold W. Stockbrügger
    • 1
  1. 1.Department of GastroenterologyUniversity Hospital MaastrichtMaastrichtThe Netherlands

Personalised recommendations